Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This was a retrospective study of 238 patients, including 92 with type-2 DM (DM2) and 11 with type-1 DM (DM1), having routine whole body FDG PET/CT.Patients with lymphoma were excluded.
|
31769591 |
2020 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Comparisons of CT features and <sup>18</sup>F-FDG metabolic indices between benign and malignant entities, as well as among primary and secondary malignancies and lymphoma, were performed.
|
31807883 |
2020 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Burkitt's lymphoma is a lymphoma with unclear metabolic behavior at 18F-FDG-PET/CT and no validated criteria in treatment evaluation and prediction of outcome exist.
|
29966473 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The impact of early fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported.
|
30481598 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Interim and posttreatment sequential FDG PET/CT scans revealed a residual splenic mass showing markedly intense FDG uptake suspected of a residual viable lymphoma.
|
30985428 |
2019 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We prospectively evaluated 76 ALPS/ALPS-like patients including FS-7-associated surface antigen (FAS) germline mutation with (n = 4) and without lymphoma (n = 50), FAS-somatic (n = 6), ALPS-unknown (n = 6), and others (n = 10) who underwent FDG PET.
|
31693620 |
2019 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Predictions of outcome after first-line treatment for DLBCL were surprisingly good when left to the unsupervised, subjective judgment of experienced readers of lymphoma 18F-FDG-PET/CT.
|
31054023 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG PET/CT) is currently the criterion standard of lymphoma imaging and recommended through all stages of Hodgkin lymphoma management.
|
30247256 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Although <sup>18</sup>F-FDG has proved useful in the management of patients with lymphoma, the specificity of <sup>18</sup>F-FDG uptake has been critically questioned, and is not without flaws.
|
31058154 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In this case, we aim to highlight this interesting FDG PET/CT imaging finding, which can serve as a clue allowing one to strongly suggest lymphoma as the leading diagnosis.
|
30688737 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
FDG PET/CT detected unsuspected extraocular lymphoma involvement in 14% of the patients.
|
31754896 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphadenopathy Due to Kimura's Disease Mimicking Lymphoma on FDG PET/CT.
|
30688747 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
F-FDG PET/CT lymphatic node hypermetabolism is not specific to lymphoma, particularly in immunocompromised patients.
|
31274617 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Texture analysis of 18F-FDG PET/CT could effectively differentiate between RCCs and renal lymphomas.
|
31140234 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study.
|
30849131 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
18F-FDG-PET/CT has become a standard for assessing treatment response in patients with lymphoma.
|
30284376 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
FDG uptake in the lymph nodes was observed in 53.3% of the patients with lymphoma and 43.3% of the patients without lymphoma, with no difference in the number of sites, uptake pattern, or mean SUVmax.
|
30615273 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
[<sup>18</sup>F]FB-GAcDb immunoPET was further evaluated in a disseminated lymphoma (A20-hCD20) syngeneic for hCD20TM and compared to [<sup>18</sup>F]FDG PET.
|
30456475 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>18</sup>F-FDG PET/CT also detected an unsuspected synchronous lymphoma in 1 patient.
|
30237211 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
F-FDG PET/CT lymphatic node hypermetabolism is not specific to lymphoma, particularly in immunocompromised patients.
|
31107755 |
2019 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Except for SUVmin (<i>p</i>=0.971), the averages of FDG uptake metrics of lymphoma were significantly higher than those of carcinoma (<i>p</i> ≤ 0.001), with the following median values: SUV<sub>mean</sub>, 4.75 versus 2.38 g/ml (<i>P</i> < 0.001); SUV<sub>std</sub>, 2.04 versus 0.88 g/ml (<i>P</i>=0.001); SUV<sub>max</sub>, 10.69 versus 4.76 g/ml (<i>P</i>=0.001); SUV<sub>peak</sub>, 9.15 versus 2.78 g/ml (<i>P</i> < 0.001); TLG, 42.24 versus 9.90 (<i>P</i> < 0.001).
|
30930700 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Whole-body MRI versus <sup>18</sup>F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis.
|
29950864 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Newly Diagnosed Primary Gum Lymphoma on FDG PET/CT.
|
29688953 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The 18F-FDG positron-emission tomography (PET) and contrast-enhanced computerised tomography (CECT) data of all relapsed or refractory HL treated at Gustave Roussy, Villejuif, France, from 2013 to 2015 were retrospectively reviewed according to the International Harmonisation Project Cheson 2014 criteria and the LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC).
|
29360605 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Varying patterns of FDG uptake was observed across various lymphoma entities; hence, interpretation of FDG-PET scans should be in the context of the tumor architecture and the prevalence of cellular population, in particular, neoplastic vs non-neoplastic inflammatory cells present in tissue microenvironment.
|
29195613 |
2018 |